Cocrystal Pharma Q4 EPS $(0.44) Beats $(0.60) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cocrystal Pharma (NASDAQ:COCP) reported Q4 losses of $(0.44) per share, surpassing the analyst consensus estimate of $(0.60) by 26.67%. This represents an 18.52% improvement over the previous year's losses of $(0.54) per share.
March 28, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cocrystal Pharma reported a smaller than expected Q4 loss of $(0.44) per share, beating the $(0.60) estimate and improving from last year's $(0.54) loss.
Beating earnings estimates typically leads to positive investor sentiment, as it indicates the company is performing better than expected. The improvement over last year's losses further strengthens the case for a potential short-term positive impact on COCP's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100